Four specific genes serve as a telltale clue to how potentially deadly stomach cancers will develop and progress, a new study ...

Researchers using next-generation DNA sequencing have identified four specific genes whose mutations are linked to the ...

Four specific genes serve as a telltale clue to how potentially deadly stomach cancers will develop and progress, a new study ...

As technology continues to evolve, the potential for innovative approaches to cancer detection and therapy becomes increasingly promising. This Research ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

MIAMI, FLORIDA (April 9, 2025) – A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center , part of the University of ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs. Jennifer Chan, MD, MPH, ...